Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877694 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT01877694 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 217 participants.
The verdict
NCT01877694, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.
Interventions
- DRUG Auriclosene Solution 0.3%
- DRUG Auriclosene Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877694
The ClinicalTrials.gov registry entry for NCT01877694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaBay Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Auriclosene Solution 0.3% is the first listed.
NCT01877694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877694 about?
NCT01877694 is a clinical study titled "Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis". The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned ...
What is the current status of trial NCT01877694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2013-06. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01877694?
The interventions under investigation include: Auriclosene Solution 0.3% (DRUG), Auriclosene Vehicle (DRUG).
Who is sponsoring clinical trial NCT01877694?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.